Rilparencel (REACT)
Chronic Kidney Disease (Stage 3b/4) with Type 2 Diabetes
Key Facts
About ProKidney
ProKidney's mission is to transform the treatment of chronic kidney disease by developing rilparencel, a novel autologous cell therapy designed to preserve kidney function and delay or prevent the need for dialysis or transplant. The company's key achievement is advancing this therapy into a pivotal Phase 3 clinical study (PROACT 1/REGEN-006), supported by RMAT designation and promising Phase 2 data. Its strategy leverages a proprietary, scalable manufacturing platform for a personalized therapy that avoids the need for chronic immunosuppression, targeting a large, underserved patient population with significant commercial potential.
View full company profileAbout ProKidney
ProKidney's mission is to transform the treatment of chronic kidney disease by developing rilparencel, a novel autologous cell therapy designed to preserve kidney function and delay or prevent the need for dialysis or transplant. The company's key achievement is advancing this therapy into a pivotal Phase 3 clinical study (PROACT 1/REGEN-006), supported by RMAT designation and promising Phase 2 data. Its strategy leverages a proprietary, scalable manufacturing platform for a personalized therapy that avoids the need for chronic immunosuppression, targeting a large, underserved patient population with significant commercial potential.
View full company profile